Spectral AI Secures $31.7M BARDA Award to Advance DeepView Wound Diagnostics

The $31.7 million award from the Biomedical Advanced Research and Development Authority (BARDA) marks a transformative milestone for Spectral AI, providing a significant injection of non-dilutive capital that validates the clinical and strategic utility of its DeepView® System. In an era where biotech firms often face high costs of capital and dilutive equity rounds, this federal contract offers a clear runway for the Dallas-based company to advance its AI-driven diagnostic tools without compromising shareholder value. The funding is specifically earmarked to accelerate the development, clinical validation, and regulatory pathways for DeepView, particularly in the critical areas of burn care and diabetic foot ulcers (DFU).

At the core of Spectral AI’s value proposition is the DeepView® System, a platform that combines multispectral imaging with proprietary deep-learning algorithms. Unlike traditional wound assessment, which relies heavily on the subjective visual judgment of clinicians—a method that has historically shown accuracy rates as low as 50-70% for burn depth—DeepView provides an objective, data-driven analysis. By looking beneath the surface of the skin, the technology can distinguish between viable and non-viable tissue almost instantaneously. This capability is not merely a convenience; it is a clinical necessity that can prevent unnecessary surgeries, reduce hospital stays, and ensure that patients receive the correct level of care during the 'golden hours' of wound management.

“

Unlike traditional wound assessment, which relies heavily on the subjective visual judgment of clinicians—a method that has historically shown accuracy rates as low as 50-70% for burn depth—DeepView provides an objective, data-driven analysis.

BARDA’s involvement underscores the national security and public health implications of Spectral AI’s technology. BARDA, a division of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), focuses on technologies that can be deployed during mass casualty events. In a scenario involving large-scale thermal injuries, the ability to rapidly and accurately triage burn victims is a critical capability that current medical infrastructure lacks. By funding Spectral AI, the U.S. government is effectively investing in a dual-use technology that serves both everyday clinical needs in hospitals and emergency preparedness for national crises.